A Pharmacokinetic Similarity Study in Healthy Male Subjects to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of LY06006 Versus US-Prolia and EU-Prolia by Single-dose Subcutaneous Injection

NCT06095427 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: LY06006 (Denosumab Biosimilar)
BIOLOGICAL: US-Prolia (Denosumab)
BIOLOGICAL: EU-Prolia

Sponsor

Luye Pharma Group Ltd.

Collaborators

[object Object]